A Phase 1 interventional study of GSK3640254 200 mg and Caffeine 200 mg in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing GSK3640254 in HIV Infections — none open to participants now, none under way, none of them phase 3. GSK3640254 · HIV Infections.
Among the 15 studies testing GSK3640254 in HIV Infections, this one is the 10th largest by enrollment, is one of 6 that started in 2020, is one of 12 in phase 1, and was the 9th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →None of the 15 studies testing GSK3640254 in HIV Infections is open now. The open studies under HIV Infections, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 6 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 34 across the 15 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 15 have an industry lead sponsor. The 1 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 180th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2020, is one of 83 in phase 1, and was the 211th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing GSK3640254 in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single sequence study that is being conducted to investigate the potential drug-drug interaction (DDI) when GSK3640254 is co-administered with a cocktail of cytochrome P450 (CYP) enzymes and transporter probe substrates in healthy participants. This study will aid in understanding these interactions and resulting changes in exposure (if any) when drugs that are metabolized via these pathways are given in combination with GSK3640254. The study will consist of a Screening period and 3 sequential treatment regimens. Participants will be administered a single dose of probe substrate drugs (caffeine 200 milligram (mg), metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg and pravastatin 40 mg) on Day 1. Participants will then receive GSK3640254 200 mg once daily on Days 11 to 20 followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (\<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Healthcare (VH)/GlaxoSmithKline (GSK) Medical Monitor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive a single dose of treatment A: Probe substrates (caffeine 200 milligram \[mg\], metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg on Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.
Drug: GSK3640254 200 mg · Drug: Caffeine 200 mg · Drug: Metoprolol 100 mg · Drug: Montelukast 10 mg · Drug: Flurbiprofen 100 mg · Drug: Omeprazole 40 mg · Drug: Midazolam 5 mg (2.5 mL) · Drug: Digoxin 0.25 mg · Drug: Pravastatin 40 mg
GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.
Caffeine will be available as oral tablets at unit dose strength of 200 mg.
Metoprolol will be available as oral tablets at unit dose strength of 100 mg.
Montelukast will be available as oral tablets at unit dose strength of 10 mg.
Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.
Omeprazole will be available as oral capsules at unit dose strength of 40 mg.
Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).
Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.
Pravastatin will be available as oral tablet at unit dose strength of 40 mg.
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. Area under the plasma concentration-time curve from time zero to time t, to be calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Maximum Observed Plasma Concentration (Cmax) for Caffeine
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Time to Cmax (Tmax) for Caffeine
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Apparent Terminal Phase Half-life (t1/2) for Caffeine
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for Metoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Metoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Metoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Metoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Metoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for Montelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Montelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Montelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Montelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Montelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for Flurbiprofen
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Flurbiprofen
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Flurbiprofen
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Flurbiprofen
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Flurbiprofen
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for Omeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Omeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Omeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Omeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Omeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for Midazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Midazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Midazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Midazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Midazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for Digoxin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Digoxin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Digoxin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Digoxin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Digoxin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for Pravastatin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Pravastatin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Pravastatin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Pravastatin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Pravastatin
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE was defined as any untoward medical occurrence that, at any dose, results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement.
Time frame: Up to Day 26
Treatment A: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values of Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Absolute Values of Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Absolute Values of Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Hemoglobin
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Erythrocytes
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Volume
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Albumin, Globulin, Protein
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Change From Baseline in Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day -1) and Day 10
Treatment B: Change From Baseline in Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 10) and Day 20
Treatment C: Change From Baseline in Amylase, Lipase
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 20), Days 22 and 25
Treatment A: Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF)
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
Time frame: Baseline (Day 1, Pre-Dose) and Day 10
Treatment B: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1, Pre-dose) and Day 10
Treatment B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Absolute Values of Oral Temperature
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
Time frame: Baseline (Day 1, Pre-dose) and Day 10
Treatment B: Absolute Values of Oral Temperature
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Absolute Values of Oral Temperature
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Absolute Values of Pulse Rate
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
Time frame: Baseline (Day 1, Pre-dose) and Day 10
Treatment B: Absolute Values of Pulse Rate
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Absolute Values of Pulse Rate
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Absolute Values of Respiratory Rate
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
Time frame: Baseline (Day 1, Pre-dose) and Day 2
Treatment B: Absolute Values of Respiratory Rate
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Absolute Values of Respiratory Rate
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
Time frame: Baseline (Day 1, Pre-dose) and Day 10
Treatment B: Absolute Values of SBP and DBP
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Absolute Values of SBP and DBP
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Change From Baseline in Oral Temperature
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1, Pre-dose) and Day 10
Treatment B: Change From Baseline in Oral Temperature
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Change From Baseline in Oral Temperature
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Change From Baseline in Pulse Rate
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1, Pre-dose) and Day 10
Treatment B: Change From Baseline in Pulse Rate
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Change From Baseline in Pulse Rate
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Change From Baseline in Respiratory Rate
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1, Pre-dose) and Day 2
Treatment B: Change From Baseline in Respiratory Rate
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Change From Baseline in Respiratory Rate
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment A: Change From Baseline in SBP and DBP
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 1, Pre-dose) and Day 10
Treatment B: Change From Baseline in SBP and DBP
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 11, Pre-Dose) and Day 20
Treatment C: Change From Baseline in SBP and DBP
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25
Treatment C: AUC(0-t) for GSK3640254
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Treatment C: Cmax for GSK3640254
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Treatment C: Tmax for GSK3640254
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Treatment C: t1/2 for GSK3640254
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
AUC(0-t) for Alpha-hydroxymetoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for Alpha-hydroxymetoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for Alpha-hydroxymetoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for Alpha-hydroxymetoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for Alpha-hydroxymetoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for 36-hydroxymontelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukas. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for 36-hydroxymontelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for 36-hydroxymontelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for 36-hydroxymontelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for 36-hydroxymontelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for 5-hydroxyomeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for 5-hydroxyomeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for 5-hydroxyomeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for 5-hydroxyomeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for 5-hydroxyomeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-t) for 1-hydroxymidazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
AUC(0-infinity) for 1-hydroxymidazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Cmax for 1-hydroxymidazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Tmax for 1-hydroxymidazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
t1/2 for 1-hydroxymidazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of Cmax of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of Cmax of 36-hydroxymontelukast to Montelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of Cmax of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of Cmax of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of Cmax of 1-hydroxymidazolam to Midazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of Cmax of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
This study was conducted in the United States.
| Milestone | All Treated Participants |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
| Milestone | All Treated Participants |
|---|---|
| Started | 20 |
| Completed | 19 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | All Treated Participants |
|---|---|
| Started | 19 |
| Completed | 19 |
| Not completed | 0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. Area under the plasma concentration-time curve from time zero to time t, to be calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| Hour*nanograms per milliliter (h*ng/mL) | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine | 37970 ± 31.1 | 42230 ± 32.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine | 39720 ± 30.6 | 44440 ± 30.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.
| Nanograms per milliliter (ng/mL) | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Caffeine | 4340 ± 22.1 | 4110 ± 25.9 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Time to Cmax (Tmax) for Caffeine | 2.000 (1.00 to 6.00) | 3.000 (0.50 to 6.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Apparent Terminal Phase Half-life (t1/2) for Caffeine | 5.380 ± 21.2 | 6.085 ± 17.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Metoprolol | 655.0 ± 135.2 | 807.3 ± 136.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Metoprolol | 659.1 ± 134.4 | 813.1 ± 135.3 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Metoprolol | 127.4 ± 90.0 | 141.1 ± 94.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Metoprolol | 2.000 (1.00 to 6.00) | 3.000 (1.00 to 4.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Metoprolol | 4.872 ± 65.6 | 5.342 ± 59.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Montelukast | 2724 ± 19.9 | 2940 ± 18.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Montelukast | 2859 ± 20.6 | 3109 ± 18.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.
| Nanograms per milliliter (ng/mL) | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Montelukast | 379.8 ± 25.2 | 393.5 ± 19.5 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Montelukast | 5.000 (2.00 to 8.03) | 6.000 (3.00 to 8.07) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Montelukast | 5.035 ± 10.2 | 5.135 ± 7.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Flurbiprofen | 64930 ± 28.9 | 66170 ± 27.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Flurbiprofen | 66700 ± 28.1 | 68660 ± 26.7 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Flurbiprofen | 10220 ± 24.7 | 10710 ± 19.8 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Flurbiprofen | 3.000 (1.00 to 8.03) | 4.000 (1.00 to 6.07) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Flurbiprofen | 6.123 ± 31.0 | 6.088 ± 30.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Omeprazole | 728.1 ± 114.7 | 817.9 ± 82.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Omeprazole | 1127 ± 98.6 | 1093 ± 75.5 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Omeprazole | 224.4 ± 121.6 | 256.6 ± 72.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Omeprazole | 6.000 (1.50 to 12.07) | 6.000 (1.50 to 12.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Omeprazole | 1.439 ± 32.0 | 1.219 ± 28.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Midazolam | 67.11 ± 31.3 | 62.95 ± 31.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Midazolam | 70.08 ± 31.4 | 65.46 ± 31.2 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Midazolam | 15.44 ± 39.5 | 13.95 ± 42.3 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Midazolam | 1.000 (0.25 to 2.00) | 1.000 (0.25 to 4.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Midazolam | 5.756 ± 13.2 | 5.222 ± 20.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| Hours*picogram per milliliter (h*pg/mL) | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Digoxin | 16690 ± 21.7 | 17840 ± 26.9 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*pg/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Digoxin | 19180 ± 21.5 | 20090 ± 27.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.
| Picogram per milliliter (pg/mL) | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Digoxin | 1026 ± 48.3 | 1282 ± 56.5 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Digoxin | 3.000 (1.50 to 6.00) | 2.000 (1.00 to 4.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Digoxin | 40.279 ± 14.3 | 38.784 ± 12.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Pravastatin | 69.92 ± 63.9 | 51.03 ± 75.5 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Pravastatin | 72.09 ± 62.9 | 43.70 ± 47.5 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Pravastatin | 19.45 ± 79.8 | 15.19 ± 76.9 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Pravastatin | 1.500 (0.50 to 6.00) | 3.000 (1.00 to 4.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Pravastatin | 3.189 ± 43.4 | 3.156 ± 47.2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE was defined as any untoward medical occurrence that, at any dose, results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement.
| Participants | Treatment A: Probe Substrates | Treatment B: GSK3640254 200 mg | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|---|
| AEs | 1 | 5 | 5 |
| SAEs | 0 | 0 | 0 |
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| 10^9 cells per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1): Platelet count | 258.6 ± 59.14 |
| Day 10: Platelet count | 265.9 ± 60.21 |
| Baseline (Day -1): Leukocyte count | 5.64 ± 1.338 |
| Day 10: Leukocyte count | 6.30 ± 1.343 |
| Baseline (Day -1): Neutrophils | 3.1504 ± 1.25074 |
| Day 10: Neutrophils | 3.7430 ± 1.27763 |
| Baseline (Day -1): Lymphocytes | 1.8217 ± 0.39628 |
| Day 10: Lymphocytes | 1.8965 ± 0.33426 |
| Baseline (Day -1): Monocytes | 0.4890 ± 0.15889 |
| Day 10: Monocytes | 0.4515 ± 0.12708 |
| Baseline (Day -1): Eosinophils | 0.1461 ± 0.15067 |
| Day 10: Eosinophils | 0.1610 ± 0.15071 |
| Baseline (Day -1): Basophils | 0.0331 ± 0.01657 |
| Day 10: Basophils | 0.0440 ± 0.01569 |
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| 10^9 cells per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10): Platelet count | 265.9 ± 60.21 |
| Day 20: Platelet count | 261.9 ± 58.51 |
| Baseline (Day 10): Leukocyte count | 6.30 ± 1.343 |
| Day 20: Leukocyte count | 5.79 ± 1.192 |
| Baseline (Day 10): Neutrophils | 3.7430 ± 1.27763 |
| Day 20: Neutrophils | 3.2680 ± 1.17833 |
| Baseline (Day 10): Lymphocytes | 1.8965 ± 0.33426 |
| Day 20: Lymphocytes | 1.8355 ± 0.52512 |
| Baseline (Day 10): Monocytes | 0.4515 ± 0.12708 |
| Day 20: Monocytes | 0.4435 ± 0.16662 |
| Baseline (Day 10): Eosinophils | 0.1610 ± 0.15071 |
| Day 20: Eosinophils | 0.1920 ± 0.18981 |
| Baseline (Day 10): Basophils | 0.0440 ± 0.01569 |
| Day 20: Basophils | 0.0460 ± 0.02981 |
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| 10^9 cells per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20): Platelet count | 262.3 ± 60.09 |
| Day 22: Platelet count | 249.2 ± 51.84 |
| Day 25: Platelet count | 260.7 ± 54.96 |
| Baseline (Day 20): Leukocyte count | 5.86 ± 1.184 |
| Day 22: Leukocyte count | 5.81 ± 1.400 |
| Day 25: Leukocyte count | 5.98 ± 1.255 |
| Baseline (Day 20): Neutrophils | 3.3179 ± 1.18871 |
| Day 22: Neutrophils | 3.1925 ± 1.29353 |
| Day 25: Neutrophils | 3.4529 ± 1.16823 |
| Baseline (Day 20): Lymphocytes | 1.8437 ± 0.53820 |
| Day 22: Lymphocytes | 1.8787 ± 0.57389 |
| Day 25: Lymphocytes | 1.9280 ± 0.63546 |
| Baseline (Day 20): Monocytes | 0.4505 ± 0.16811 |
| Day 22: Monocytes | 0.4689 ± 0.14658 |
| Day 25: Monocytes | 0.3576 ± 0.12355 |
| Baseline (Day 20): Eosinophils | 0.1953 ± 0.19443 |
| Day 22: Eosinophils | 0.2282 ± 0.23748 |
| Day 25: Eosinophils | 0.1837 ± 0.20635 |
| Baseline (Day 20): Basophils | 0.0474 ± 0.02997 |
| Day 22: Basophils | 0.0380 ± 0.02395 |
| Day 25: Basophils | 0.0408 ± 0.02134 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Proportion of red blood cells in blood | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1) | 0.4188 ± 0.03442 |
| Day 10 | 0.4098 ± 0.03577 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Proportion of red blood cells in blood | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10) | 0.4098 ± 0.03577 |
| Day 20 | 0.4216 ± 0.03420 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Proportion of red blood cells in blood | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20) | 0.4239 ± 0.03352 |
| Day 22 | 0.4022 ± 0.04433 |
| Day 25 | 0.4168 ± 0.04079 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Grams per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1) | 141.9 ± 13.27 |
| Day 10 | 137.7 ± 13.07 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Grams per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10) | 137.7 ± 13.07 |
| Day 20 | 140.0 ± 12.22 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Grams per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20) | 140.6 ± 12.21 |
| Day 22 | 134.7 ± 15.54 |
| Day 25 | 138.3 ± 13.83 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| 10^12 cells per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1) | 4.836 ± 0.4125 |
| Day 10 | 4.664 ± 0.4459 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| 10^12 cells per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10) | 4.664 ± 0.4459 |
| Day 20 | 4.746 ± 0.3994 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| 10^12 cells per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20) | 4.769 ± 0.3966 |
| Day 22 | 4.608 ± 0.5308 |
| Day 25 | 4.756 ± 0.4718 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Femtoliter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1) | 86.71 ± 3.748 |
| Day 10 | 88.02 ± 3.938 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Femtoliter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10) | 88.02 ± 3.938 |
| Day 20 | 88.96 ± 4.746 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Femtoliter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20) | 89.03 ± 4.865 |
| Day 22 | 87.38 ± 4.217 |
| Day 25 | 87.74 ± 4.045 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Picograms | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1) | 29.37 ± 1.546 |
| Day 10 | 29.57 ± 1.667 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Picograms | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10) | 29.57 ± 1.667 |
| Day 20 | 29.52 ± 1.602 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Picograms | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20) | 29.51 ± 1.645 |
| Day 22 | 29.28 ± 1.670 |
| Day 25 | 29.12 ± 1.626 |
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Millimoles per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1): Glucose | 5.0348 ± 0.37437 |
| Day 10: Glucose | 4.8211 ± 0.44125 |
| Baseline (Day -1): Carbon Dioxide | 104.1 ± 2.04 |
| Day 10: Carbon Dioxide | 25.4 ± 2.11 |
| Baseline (Day -1): Cholesterol | 4.4570 ± 1.00121 |
| Day 10: Cholesterol | 3.8118 ± 0.85065 |
| Baseline (Day -1): Triglycerides | 1.2232 ± 0.51018 |
| Day 10: Triglycerides | 1.1814 ± 0.82178 |
| Baseline (Day -1): Anion Gap | 7.9 ± 1.80 |
| Day 10: Anion Gap | 13.8 ± 1.71 |
| Baseline (Day -1): Calcium | 2.3765 ± 0.09976 |
| Day 10: Calcium | 2.3141 ± 0.10267 |
| Baseline (Day -1): Chloride | 25.8 ± 2.10 |
| Day 10: Chloride | 103.7 ± 1.81 |
| Baseline (Day -1): Phosphate | 1.1075 ± 0.16734 |
| Day 10: Phosphate | 1.1754 ± 0.16141 |
| Baseline (Day -1): Potassium | 4.48 ± 0.339 |
| Day 10: Potassium | 4.43 ± 0.256 |
| Baseline (Day -1): Sodium | 137.7 ± 2.00 |
| Day 10: Sodium | 138.4 ± 1.93 |
| Baseline (Day -1): Urea | 4.8195 ± 0.78983 |
| Day 10: Urea | 5.9458 ± 1.43309 |
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Millimoles per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10): Glucose | 4.8211 ± 0.44125 |
| Day 20: Glucose | 4.7378 ± 0.45996 |
| Baseline (Day 10): Carbon Dioxide | 25.4 ± 2.11 |
| Day 20: Carbon Dioxide | 24.9 ± 2.11 |
| Baseline (Day 10): Cholesterol | 3.8118 ± 0.85065 |
| Day 20: Cholesterol | 3.6915 ± 0.94881 |
| Baseline (Day 10): Triglycerides | 1.1814 ± 0.82178 |
| Day 20: Triglycerides | 1.0825 ± 0.84563 |
| Baseline (Day 10): Anion Gap | 13.8 ± 1.71 |
| Day 20: Anion Gap | 14.5 ± 2.12 |
| Baseline (Day 10): Calcium | 2.3141 ± 0.10267 |
| Day 20: Calcium | 2.3141 ± 0.08825 |
| Baseline (Day 10): Chloride | 103.7 ± 1.81 |
| Day 20: Chloride | 103.6 ± 2.30 |
| Baseline (Day 10): Phosphate | 1.1754 ± 0.16141 |
| Day 20: Phosphate | 1.2593 ± 0.13294 |
| Baseline (Day 10): Potassium | 4.43 ± 0.256 |
| Day 20: Potassium | 4.39 ± 0.383 |
| Baseline (Day 10): Sodium | 138.4 ± 1.93 |
| Day 20: Sodium | 138.6 ± 1.64 |
| Baseline (Day 10): Urea | 5.9458 ± 1.43309 |
| Day 20: Urea | 5.6335 ± 1.72537 |
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Millimoles per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20): Glucose | 4.7184 ± 0.46406 |
| Day 22: Glucose | 4.8060 ± 0.37890 |
| Day 25: Glucose | 4.8703 ± 0.40699 |
| Baseline (Day 20): Carbon Dioxide | 24.9 ± 2.12 |
| Day 22: Carbon Dioxide | 25.4 ± 1.74 |
| Day 25: Carbon Dioxide | 26.2 ± 1.80 |
| Baseline (Day 20): Cholesterol | 3.6898 ± 0.97478 |
| Day 22: Cholesterol | 3.2543 ± 0.88216 |
| Day 25: Cholesterol | 3.3972 ± 0.89603 |
| Baseline (Day 20): Triglycerides | 1.0783 ± 0.86858 |
| Day 22: Triglycerides | 1.0836 ± 0.78925 |
| Day 25: Triglycerides | 1.1074 ± 0.81372 |
| Baseline (Day 20): Anion Gap | 14.6 ± 2.14 |
| Day 22: Anion Gap | 13.9 ± 1.27 |
| Day 25: Anion Gap | 14.5 ± 1.95 |
| Baseline (Day 20): Calcium | 2.3217 ± 0.08377 |
| Day 22: Calcium | 2.2810 ± 0.10822 |
| Day 25: Calcium | 2.3519 ± 0.09440 |
| Baseline (Day 20): Chloride | 103.4 ± 2.22 |
| Day 22: Chloride | 104.8 ± 2.02 |
| Day 25: Chloride | 102.6 ± 1.86 |
| Baseline (Day 20): Phosphate | 1.2661 ± 0.13297 |
| Day 22: Phosphate | 1.1981 ± 0.14871 |
| Day 25: Phosphate | 1.3477 ± 0.18638 |
| Baseline (Day 20): Potassium | 4.38 ± 0.392 |
| Day 22: Potassium | 4.34 ± 0.347 |
| Day 25: Potassium | 4.35 ± 0.355 |
| Baseline (Day 20): Sodium | 138.6 ± 1.67 |
| Day 22: Sodium | 139.8 ± 1.34 |
| Day 25: Sodium | 139.0 ± 1.67 |
| Baseline (Day 20): Urea | 5.7364 ± 1.70835 |
| Day 22: Urea | 4.9078 ± 1.44100 |
| Day 25: Urea | 5.3099 ± 1.18355 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Micromoles per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1): Urate | 347.3632 ± 69.50981 |
| Day 10: Urate | 365.5046 ± 75.74195 |
| Baseline (Day -1): Creatinine | 84.9524 ± 19.89935 |
| Day 10: Creatinine | 86.4110 ± 21.46247 |
| Baseline (Day -1): Bilirubin | 9.8325 ± 3.13227 |
| Day 10: Bilirubin | 8.0028 ± 3.01005 |
| Baseline (Day -1): Direct bilirubin | 2.0520 ± 0.70177 |
| Day 10: Direct bilirubin | 1.7015 ± 0.63856 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Micromoles per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10): Urate | 365.5046 ± 75.74195 |
| Day 20: Urate | 337.8464 ± 76.60060 |
| Baseline (Day 10): Creatinine | 86.4110 ± 21.46247 |
| Day 20: Creatinine | 90.7868 ± 22.81174 |
| Baseline (Day 10): Bilirubin | 8.0028 ± 3.01005 |
| Day 20: Bilirubin | 8.6184 ± 3.04856 |
| Baseline (Day 10): Direct bilirubin | 1.7015 ± 0.63856 |
| Day 20: Direct bilirubin | 1.8126 ± 0.64557 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Micromoles per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20): Urate | 343.1057 ± 74.89791 |
| Day 22: Urate | 303.0349 ± 71.88291 |
| Day 25: Urate | 340.6013 ± 67.89995 |
| Baseline (Day 20): Creatinine | 92.1686 ± 22.56047 |
| Day 22: Creatinine | 87.3764 ± 22.63812 |
| Day 25: Creatinine | 90.5867 ± 21.29029 |
| Baseline (Day 20): Bilirubin | 8.7480 ± 3.07497 |
| Day 22: Bilirubin | 9.8820 ± 3.24579 |
| Day 25: Bilirubin | 9.0360 ± 3.89534 |
| Baseline (Day 20): Direct bilirubin | 1.8450 ± 0.64634 |
| Day 22: Direct bilirubin | 2.0790 ± 0.60930 |
| Day 25: Direct bilirubin | 1.9980 ± 0.70286 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Grams per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1): Albumin | 42.9 ± 2.95 |
| Day 10: Albumin | 42.2 ± 3.14 |
| Baseline (Day -1): Globulin | 27.4 ± 3.14 |
| Day 10: Globulin | 25.9 ± 3.04 |
| Baseline (Day -1): Protein | 70.3 ± 4.52 |
| Day 10: Protein | 68.1 ± 3.77 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Grams per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10): Albumin | 42.2 ± 3.14 |
| Day 20: Albumin | 41.4 ± 3.31 |
| Baseline (Day 10): Globulin | 25.9 ± 3.04 |
| Day 20: Globulin | 26.8 ± 3.58 |
| Baseline (Day 10): Protein | 68.1 ± 3.77 |
| Day 20: Protein | 68.2 ± 4.93 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Grams per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20): Albumin | 41.6 ± 3.24 |
| Day 22: Albumin | 40.5 ± 3.82 |
| Day 25: Albumin | 42.0 ± 3.04 |
| Baseline (Day 20): Globulin | 26.9 ± 3.65 |
| Day 22: Globulin | 25.1 ± 3.69 |
| Day 25: Globulin | 26.6 ± 3.67 |
| Baseline (Day 20): Protein | 68.5 ± 4.85 |
| Day 22: Protein | 65.6 ± 5.74 |
| Day 25: Protein | 68.6 ± 4.34 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| International units per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1): Creatine kinase | 103.7 ± 79.68 |
| Day 10: Creatine kinase | 66.9 ± 34.67 |
| Baseline (Day -1): Lactate dehydrogenase | 131.3 ± 19.59 |
| Day 10: Lactate dehydrogenase | 114.8 ± 16.87 |
| Baseline (Day -1): ALT | 15.6 ± 7.66 |
| Day 10: ALT | 20.1 ± 14.66 |
| Baseline (Day -1): ALP | 62.7 ± 18.46 |
| Day 10: ALP | 60.8 ± 18.03 |
| Baseline (Day -1): AST | 14.6 ± 3.89 |
| Day 10: AST | 15.6 ± 5.32 |
| Baseline (Day -1): Gamma-glutamyl transferase | 19.1 ± 7.16 |
| Day 10: Gamma-glutamyl transferase | 18.9 ± 8.10 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| International units per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10): Creatine kinase | 66.9 ± 34.67 |
| Day 20: Creatine kinase | 68.9 ± 47.98 |
| Baseline (Day 10): Lactate dehydrogenase | 114.8 ± 16.87 |
| Day 20: Lactate dehydrogenase | 115.9 ± 17.00 |
| Baseline (Day 10): ALT | 20.1 ± 14.66 |
| Day 20: ALT | 20.3 ± 12.38 |
| Baseline (Day 10): ALP | 60.8 ± 18.03 |
| Day 20: ALP | 58.5 ± 15.56 |
| Baseline (Day 10): AST | 15.6 ± 5.32 |
| Day 20: AST | 16.1 ± 4.80 |
| Baseline (Day 10): Gamma-glutamyl transferase | 18.9 ± 8.10 |
| Day 20: Gamma-glutamyl transferase | 18.3 ± 7.69 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| International units per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20): Creatine kinase | 71.3 ± 48.03 |
| Day 22: Creatine kinase | 65.7 ± 34.56 |
| Day 25: Creatine kinase | 63.8 ± 30.90 |
| Baseline (Day 20): Lactate dehydrogenase | 116.6 ± 17.13 |
| Day 22: Lactate dehydrogenase | 120.6 ± 23.62 |
| Day 25: Lactate dehydrogenase | 119.3 ± 19.18 |
| Baseline (Day 20): ALT | 20.4 ± 12.70 |
| Day 22: ALT | 17.3 ± 9.36 |
| Day 25: ALT | 20.9 ± 11.92 |
| Baseline (Day 20): ALP | 58.5 ± 15.98 |
| Day 22: ALP | 57.6 ± 16.26 |
| Day 25:ALP | 58.6 ± 16.40 |
| Baseline (Day 20): AST | 16.2 ± 4.91 |
| Day 22: AST | 14.7 ± 3.78 |
| Day 25: AST | 16.4 ± 4.56 |
| Baseline (Day 20): Gamma-glutamyl transferase | 18.5 ± 7.83 |
| Day 22: Gamma-glutamyl transferase | 17.1 ± 6.77 |
| Day 25: Gamma-glutamyl transferase | 18.7 ± 8.23 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.
| Units per liter | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day -1): Lipase | 29.4 ± 14.73 |
| Day 10: Lipase | 31.6 ± 11.99 |
| Baseline (Day -1): Amylase | 59.5 ± 22.37 |
| Day 10: Amylase | 56.9 ± 20.93 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.
| Units per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 10): Lipase | 31.6 ± 11.99 |
| Day 20: Lipase | 32.4 ± 14.51 |
| Baseline (Day 10): Amylase | 56.9 ± 20.93 |
| Day 20: Amylase | 60.1 ± 23.22 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.
| Units per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 20): Lipase | 32.9 ± 14.74 |
| Day 22: Lipase | 33.5 ± 15.19 |
| Day 25: Lipase | 33.1 ± 14.58 |
| Baseline (Day 20): Amylase | 62.2 ± 21.79 |
| Day 22: Amylase | 64.7 ± 25.32 |
| Day 25: Amylase | 60.7 ± 21.08 |
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^9 cells per liter | Treatment A: Probe Substrates |
|---|---|
| Platelet count | 7.3 ± 20.01 |
| Leukocyte count | 0.66 ± 0.844 |
| Neutrophils | 0.5926 ± 0.68577 |
| Lymphocytes | 0.0748 ± 0.25872 |
| Monocytes | -0.0375 ± 0.09379 |
| Eosinophils | 0.0150 ± 0.07023 |
| Basophils | 0.0110 ± 0.02138 |
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^9 cells per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Platelet count | -4.1 ± 17.31 |
| Leukocyte count | -0.51 ± 0.947 |
| Neutrophils | -0.4750 ± 0.63752 |
| Lymphocytes | -0.0610 ± 0.39045 |
| Monocytes | -0.0080 ± 0.11134 |
| Eosinophils | 0.0310 ± 0.10686 |
| Basophils | 0.0020 ± 0.02526 |
Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^9 cells per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: Platelet count | -13.1 ± 19.31 |
| Day 25: Platelet count | -1.6 ± 24.62 |
| Day 22: Leukocyte count | -0.05 ± 0.906 |
| Day 25: Leukocyte count | 0.12 ± 0.820 |
| Day 22: Neutrophils | -0.1254 ± 0.74916 |
| Day 25: Neutrophils | 0.1351 ± 0.72701 |
| Day 22: Lymphocytes | 0.0351 ± 0.42962 |
| Day 25: Lymphocytes | 0.0843 ± 0.41536 |
| Day 22: Monocytes | 0.0184 ± 0.08808 |
| Day 25: Monocytes | -0.0929 ± 0.17694 |
| Day 22: Eosinophils | 0.0329 ± 0.12007 |
| Day 25: Eosinophils | -0.0115 ± 0.06076 |
| Day 22: Basophils | -0.0094 ± 0.03787 |
| Day 25: Basophils | -0.0066 ± 0.03173 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Proportion of red blood cells in blood | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Hematocrit | -0.0090 ± 0.02082 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Proportion of red blood cells in blood | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Hematocrit | 0.0118 ± 0.01667 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Proportion of red blood cells in blood | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -0.0217 ± 0.02090 |
| Day 25 | -0.0071 ± 0.02129 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Hemoglobin | -4.2 ± 6.34 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Hemoglobin | 2.3 ± 4.91 |
Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -5.8 ± 6.52 |
| Day 25 | -2.3 ± 5.82 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^12 cells per liter | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Erythrocytes | -0.172 ± 0.2219 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^12 cells per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Erythrocytes | 0.083 ± 0.1768 |
Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| 10^12 cells per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -0.161 ± 0.2190 |
| Day 25 | -0.013 ± 0.2027 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Femtoliter | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume | 1.31 ± 1.539 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Femtoliter | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume | 0.94 ± 2.519 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Femtoliter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -1.64 ± 1.849 |
| Day 25 | -1.28 ± 2.234 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Picograms | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin | 0.20 ± 0.352 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Picograms | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin | -0.05 ± 0.298 |
Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Picograms | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -0.23 ± 0.407 |
| Day 25 | -0.39 ± 0.519 |
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimoles per liter | Treatment A: Probe Substrates |
|---|---|
| Glucose | -0.2137 ± 0.29663 |
| Carbon Dioxide | -78.7 ± 3.12 |
| Cholesterol | -0.6452 ± 0.47501 |
| Triglycerides | -0.0418 ± 0.59458 |
| Anion Gap | 5.9 ± 2.21 |
| Calcium | -0.0624 ± 0.04889 |
| Chloride | 78.0 ± 2.98 |
| Phosphate | 0.0678 ± 0.10522 |
| Potassium | -0.05 ± 0.402 |
| Sodium | 0.7 ± 2.16 |
| Urea | 1.1263 ± 0.97483 |
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimoles per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Glucose | -0.0833 ± 0.29345 |
| Carbon Dioxide | -0.6 ± 1.79 |
| Cholesterol | -0.1203 ± 0.30774 |
| Triglycerides | -0.0989 ± 0.30531 |
| Anion Gap | 0.8 ± 1.94 |
| Calcium | 0.0000 ± 0.06575 |
| Chloride | -0.1 ± 1.52 |
| Phosphate | 0.0840 ± 0.08601 |
| Potassium | -0.05 ± 0.378 |
| Sodium | 0.3 ± 1.41 |
| Urea | -0.3124 ± 0.72202 |
Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimoles per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: Glucose | 0.0876 ± 0.29392 |
| Day 25: Glucose | 0.1519 ± 0.32570 |
| Day 22: Carbon Dioxide | 0.5 ± 2.12 |
| Day 25: Carbon Dioxide | 1.2 ± 1.81 |
| Day 22: Cholesterol | -0.4355 ± 0.31287 |
| Day 25: Cholesterol | -0.2926 ± 0.25147 |
| Day 22: Triglycerides | 0.0054 ± 0.14595 |
| Day 25: Triglycerides | 0.0291 ± 0.18280 |
| Day 22: Anion Gap | -0.6 ± 1.80 |
| Day 25: Anion Gap | -0.1 ± 0.97 |
| Day 22: Calcium | -0.0407 ± 0.07165 |
| Day 25: Calcium | 0.0302 ± 0.05553 |
| Day 22: Chloride | 1.4 ± 1.64 |
| Day 25: Chloride | -0.8 ± 1.78 |
| Day 22: Phosphate | -0.0680 ± 0.09860 |
| Day 25: Phosphate | 0.0816 ± 0.09527 |
| Day 22: Potassium | -0.04 ± 0.373 |
| Day 25: Potassium | -0.03 ± 0.441 |
| Day 22: Sodium | 1.2 ± 1.51 |
| Day 25: Sodium | 0.4 ± 2.41 |
| Day 22: Urea | -0.8286 ± 0.88169 |
| Day 25: Urea | -0.4265 ± 0.85981 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Micromoles per liter | Treatment A: Probe Substrates |
|---|---|
| Urate | 18.1414 ± 39.28786 |
| Creatinine | 1.4586 ± 5.65145 |
| Bilirubin | -1.8297 ± 1.38266 |
| Direct bilirubin | -0.3506 ± 0.60895 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Micromoles per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Urate | -27.6582 ± 25.47573 |
| Creatinine | 4.3758 ± 4.38239 |
| Bilirubin | 0.6156 ± 1.92059 |
| Direct bilirubin | 0.1112 ± 0.46509 |
Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Micromoles per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: Urate | -40.0707 ± 26.51457 |
| Day 25: Urate | -2.5044 ± 26.62359 |
| Day 22: Creatinine | -4.7922 ± 5.82901 |
| Day 25: Creatinine | -1.5819 ± 4.60830 |
| Day 22: Bilirubin | 1.1340 ± 1.91202 |
| Day 25: Bilirubin | 0.2880 ± 2.14494 |
| Day 22: Direct bilirubin | 0.2340 ± 0.38326 |
| Day 25: Direct bilirubin | 0.1530 ± 0.39447 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Treatment A: Probe Substrates |
|---|---|
| Albumin | -0.7 ± 1.75 |
| Globulin | -1.5 ± 1.61 |
| Protein | -2.2 ± 2.57 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Albumin | -0.9 ± 2.43 |
| Globulin | 0.9 ± 2.07 |
| Protein | 0.1 ± 3.71 |
Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Grams per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: Albumin | -1.1 ± 2.44 |
| Day 25: Albumin | 0.4 ± 1.71 |
| Day 22: Globulin | -1.8 ± 1.98 |
| Day 25: Globulin | -0.3 ± 1.76 |
| Day 22: Protein | -2.9 ± 4.15 |
| Day 25: Protein | 0.2 ± 2.81 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| International units per liter | Treatment A: Probe Substrates |
|---|---|
| Creatine kinase | -36.9 ± 59.38 |
| Lactate dehydrogenase | -16.5 ± 15.50 |
| ALT | 4.5 ± 11.51 |
| ALP | -1.9 ± 6.39 |
| AST | 1.0 ± 4.52 |
| Gamma-glutamyl transferase | -0.2 ± 3.86 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| International units per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Creatine kinase | 2.1 ± 24.48 |
| Lactate dehydrogenase | 1.1 ± 13.15 |
| ALT | 0.3 ± 6.78 |
| ALP | -2.4 ± 6.21 |
| AST | 0.6 ± 3.03 |
| Gamma-glutamyl transferase | -0.6 ± 2.74 |
Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| International units per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: Creatine kinase | -5.6 ± 21.78 |
| Day 25: Creatine kinase | -7.5 ± 26.10 |
| Day 22: Lactate dehydrogenase | 4.0 ± 18.94 |
| Day 25: Lactate dehydrogenase | 2.6 ± 16.30 |
| Day 22: ALT | -3.1 ± 4.12 |
| Day 25: ALT | 0.5 ± 2.61 |
| Day 22: ALP | -0.9 ± 5.83 |
| Day 25:ALP | 0.1 ± 3.91 |
| Day 22: AST | -1.5 ± 2.78 |
| Day 25: AST | 0.2 ± 1.89 |
| Day 22: Gamma-glutamyl transferase | -1.5 ± 1.61 |
| Day 25: Gamma-glutamyl transferase | 0.2 ± 1.26 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Units per liter | Treatment A: Probe Substrates |
|---|---|
| Lipase | 2.2 ± 6.81 |
| Amylase | -2.6 ± 7.86 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Units per liter | Treatment B: GSK3640254 200 mg |
|---|---|
| Lipase | 0.9 ± 6.07 |
| Amylase | 3.2 ± 6.31 |
Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Units per liter | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: Lipase | 0.6 ± 10.08 |
| Day 25: Lipase | 0.2 ± 4.88 |
| Day 22: Amylase | 2.5 ± 7.10 |
| Day 25: Amylase | -1.5 ± 4.98 |
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
| Milliseconds | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day 1, Pre-dose): PR Interval | 154.8 ± 20.92 |
| Day 10: PR Interval | 158.2 ± 22.67 |
| Baseline (Day 1, Pre-dose): QRS Duration | 92.5 ± 8.34 |
| Day 10: QRS Duration | 95.0 ± 10.11 |
| Baseline (Day 1, Pre-dose): QT Interval | 391.2 ± 22.41 |
| Day 10: QT Interval | 398.3 ± 22.19 |
| Baseline (Day 1, Pre-dose): QTcF Interval | 401.0 ± 16.48 |
| Day 10: QTcF Interval | 405.8 ± 16.25 |
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
| Milliseconds | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 11, Pre-dose): PR Interval | 158.6 ± 19.44 |
| Day 20: PR Interval | 161.8 ± 22.40 |
| Baseline (Day 11, Pre-dose): QRS Duration | 94.2 ± 8.73 |
| Day 20: QRS Duration | 96.4 ± 9.25 |
| Baseline (Day 11, Pre-dose): QT Interval | 403.1 ± 26.27 |
| Day 20: QT Interval | 408.8 ± 25.85 |
| Baseline (Day 11, Pre-dose): QTcF Interval | 403.5 ± 17.63 |
| Day 20: QTcF Interval | 408.6 ± 17.26 |
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
| Milliseconds | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 21, Pre-dose): PR Interval | 160.8 ± 20.26 |
| Day 22: PR Interval | 162.3 ± 22.07 |
| Day 25: PR Interval | 159.6 ± 23.55 |
| Baseline (Day 21, Pre-dose): QRS Duration | 95.8 ± 9.49 |
| Day 22: QRS Duration | 98.7 ± 10.30 |
| Day 25: QRS Duration | 96.8 ± 8.42 |
| Baseline (Day 21, Pre-dose): QT Interval | 402.6 ± 21.06 |
| Day 22: QT Interval | 420.6 ± 21.16 |
| Day 25: QT Interval | 398.7 ± 22.25 |
| Baseline (Day 21, Pre-dose): QTcF Interval | 408.7 ± 16.31 |
| Day 22: QTcF Interval | 407.3 ± 13.75 |
| Day 25: QTcF Interval | 402.5 ± 17.03 |
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Milliseconds | Treatment A: Probe Substrates |
|---|---|
| PR Interval | 3.4 ± 9.28 |
| QRS Duration | 2.5 ± 4.37 |
| QT Interval | 7.1 ± 12.81 |
| QTcF Interval | 4.8 ± 9.27 |
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Milliseconds | Treatment B: GSK3640254 200 mg |
|---|---|
| PR Interval | 3.2 ± 8.79 |
| QRS Duration | 2.3 ± 2.77 |
| QT Interval | 5.7 ± 13.30 |
| QTcF Interval | 5.1 ± 10.69 |
Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Milliseconds | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: PR Interval | 1.5 ± 9.99 |
| Day 25: PR Interval | -1.2 ± 10.07 |
| Day 22: QRS Duration | 2.9 ± 4.24 |
| Day 25: QRS Duration | 1.0 ± 3.43 |
| Day 22: QT Interval | 18.0 ± 20.32 |
| Day 25: QT Interval | -3.9 ± 16.18 |
| Day 22: QTcF Interval | -1.4 ± 9.44 |
| Day 25: QTcF Interval | -6.3 ± 8.41 |
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
| Degrees Celsius | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day 1, Pre-dose) | 36.38 ± 0.293 |
| Day 10 | 36.26 ± 0.252 |
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
| Degrees Celsius | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 11, Pre-dose) | 36.31 ± 0.320 |
| Day 20 | 36.28 ± 0.246 |
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
| Degrees Celsius | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 21, Pre-dose) | 36.31 ± 0.284 |
| Day 22 | 36.18 ± 0.210 |
| Day 25 | 36.31 ± 0.300 |
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
| Beats per minute | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day 1, Pre-dose) | 64.5 ± 8.97 |
| Day 10 | 65.0 ± 8.19 |
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
| Beats per minute | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 11, Pre-dose) | 61.6 ± 9.95 |
| Day 20 | 62.8 ± 10.22 |
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
| Beats per minute | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 21, Pre-dose) | 63.2 ± 7.04 |
| Day 22 | 56.2 ± 6.83 |
| Day 25 | 61.7 ± 7.27 |
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
| Breaths per minute | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day 1, Pre-dose) | 16.1 ± 1.37 |
| Day 2 | 15.8 ± 2.33 |
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
| Breaths per minute | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 11, Pre-dose) | 15.0 ± 2.29 |
| Day 20 | 14.7 ± 2.27 |
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
| Breaths per minute | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 21, Pre-dose) | 15.7 ± 1.56 |
| Day 22 | 15.7 ± 1.38 |
| Day 25 | 16.5 ± 2.20 |
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.
| Millimeters of mercury | Treatment A: Probe Substrates |
|---|---|
| Baseline (Day 1, Pre-dose): SBP | 111.0 ± 9.03 |
| Day 10: SBP | 107.7 ± 9.32 |
| Baseline (Day 1, Pre-dose): DBP | 65.1 ± 6.73 |
| Day 10: DBP | 59.7 ± 6.24 |
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.
| Millimeters of mercury | Treatment B: GSK3640254 200 mg |
|---|---|
| Baseline (Day 11, Pre-dose): SBP | 107.7 ± 8.46 |
| Day 20: SBP | 107.2 ± 9.52 |
| Baseline (Day 11, Pre-dose): DBP | 61.6 ± 6.56 |
| Day 20: DBP | 59.6 ± 5.55 |
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.
| Millimeters of mercury | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Baseline (Day 21, Pre-dose): SBP | 107.5 ± 8.49 |
| Day 22: SBP | 105.6 ± 11.93 |
| Day 25: SBP | 109.7 ± 7.96 |
| Baseline (Day 21, Pre-dose): DBP | 62.7 ± 5.31 |
| Day 22: DBP | 58.4 ± 5.87 |
| Day 25: DBP | 62.2 ± 5.06 |
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Degrees Celsius | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Oral Temperature | -0.12 ± 0.314 |
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Degrees Celsius | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Oral Temperature | -0.03 ± 0.249 |
Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Degrees Celsius | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -0.13 ± 0.242 |
| Day 25 | 0.01 ± 0.286 |
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Beats per minute | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Pulse Rate | 0.5 ± 6.27 |
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Beats per minute | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Pulse Rate | 1.3 ± 7.44 |
Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Beats per minute | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -7.1 ± 7.48 |
| Day 25 | -1.5 ± 6.17 |
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Breaths per minute | Treatment A: Probe Substrates |
|---|---|
| Treatment A: Change From Baseline in Respiratory Rate | -0.3 ± 2.62 |
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Breaths per minute | Treatment B: GSK3640254 200 mg |
|---|---|
| Treatment B: Change From Baseline in Respiratory Rate | -0.3 ± 2.36 |
Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Breaths per minute | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22 | -0.1 ± 1.90 |
| Day 25 | 0.8 ± 2.37 |
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimeters of mercury | Treatment A: Probe Substrates |
|---|---|
| SBP | -3.3 ± 9.67 |
| DBP | -5.4 ± 5.96 |
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimeters of mercury | Treatment B: GSK3640254 200 mg |
|---|---|
| SBP | -0.5 ± 8.56 |
| DBP | -2.0 ± 5.75 |
SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.
| Millimeters of mercury | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Day 22: SBP | -1.9 ± 10.84 |
| Day 25: SBP | 2.2 ± 8.67 |
| Day 22: DBP | -4.3 ± 4.75 |
| Day 25: DBP | -0.5 ± 4.78 |
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Treatment C: AUC(0-t) for GSK3640254 | 51840 ± 48.8 |
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
| h*ng/mL | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254 | 22920 ± 37.3 |
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
| ng/mL | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Treatment C: Cmax for GSK3640254 | 1450 ± 41.7 |
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
| ng/mL | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254 | 729.5 ± 35.5 |
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
| Hours | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Treatment C: Tmax for GSK3640254 | 4.500 (2.00 to 8.03) |
Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.
| Hours | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|
| Treatment C: t1/2 for GSK3640254 | 29.556 ± 16.9 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for Alpha-hydroxymetoprolol | 531.3 ± 159.4 | 487.9 ± 174.4 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for Alpha-hydroxymetoprolol | 682.8 ± 34.1 | 632.8 ± 50.7 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for Alpha-hydroxymetoprolol | 45.70 ± 199.8 | 39.21 ± 212.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for Alpha-hydroxymetoprolol | 3.033 (1.00 to 6.00) | 4.000 (1.00 to 8.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for Alpha-hydroxymetoprolol | 8.040 ± 31.4 | 8.339 ± 23.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukas. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for 36-hydroxymontelukast | 234.2 ± 47.2 | 230.9 ± 59.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for 36-hydroxymontelukast | 252.5 ± 48.2 | 249.3 ± 58.7 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for 36-hydroxymontelukast | 24.62 ± 45.7 | 23.22 ± 55.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for 36-hydroxymontelukast | 6.000 (3.00 to 8.03) | 6.000 (4.00 to 8.13) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for 36-hydroxymontelukast | 5.310 ± 14.3 | 5.644 ± 15.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for 5-hydroxyomeprazole | 713.5 ± 38.0 | 785.1 ± 24.7 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for 5-hydroxyomeprazole | 767.4 ± 30.9 | 762.0 ± 25.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for 5-hydroxyomeprazole | 181.1 ± 63.1 | 203.3 ± 28.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for 5-hydroxyomeprazole | 6.000 (2.05 to 12.07) | 6.000 (1.50 to 12.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for 5-hydroxyomeprazole | 1.580 ± 15.4 | 1.569 ± 13.5 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-t) for 1-hydroxymidazolam | 31.07 ± 33.0 | 28.07 ± 37.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.
| h*ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| AUC(0-infinity) for 1-hydroxymidazolam | 31.86 ± 32.5 | 28.99 ± 36.6 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.
| ng/mL | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Cmax for 1-hydroxymidazolam | 7.933 ± 53.8 | 6.722 ± 48.1 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Tmax for 1-hydroxymidazolam | 1.000 (0.25 to 3.00) | 1.000 (0.25 to 4.00) |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.
| Hours | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| t1/2 for 1-hydroxymidazolam | 3.632 ± 15.6 | 3.717 ± 21.0 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of Cmax of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol | 0.7869 ± 0.76896 | 0.7066 ± 0.93732 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol | 1.733 ± 1.6208 | 1.449 ± 1.6511 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of Cmax of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of Cmax of 36-hydroxymontelukast to Montelukast | 0.06766 ± 0.025068 | 0.06308 ± 0.025951 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast | 0.09182 ± 0.033472 | 0.08562 ± 0.036555 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of Cmax of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole | 0.9461 ± 0.56833 | 0.8810 ± 0.49954 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole | 1.151 ± 0.66463 | 1.077 ± 0.59178 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of Cmax of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of Cmax of 1-hydroxymidazolam to Midazolam | 0.5286 ± 0.23819 | 0.4955 ± 0.20616 |
Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.
| Ratio | Treatment A: Probe Substrates | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|
| Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam | 0.4677 ± 0.19853 | 0.4618 ± 0.20637 |
Collected over All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 26. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A: Probe Substrates | 0/20 (0%) | 0/20 (0%) | 1/20 (5%) |
| Treatment B: GSK3640254 200 mg | 0/20 (0%) | 0/20 (0%) | 5/20 (25%) |
| Treatment C: Probe Substrates + GSK3640254 200 mg | 0/19 (0%) | 0/19 (0%) | 5/19 (26.3%) |
| Event | Treatment A: Probe Substrates | Treatment B: GSK3640254 200 mg | Treatment C: Probe Substrates + GSK3640254 200 mg |
|---|---|---|---|
| DizzinessNervous system disorders | 0/20 | 3/20 | 0/19 |
| HeadacheNervous system disorders | 1/20 | 1/20 | 1/19 |
| Taste disorderNervous system disorders | 0/20 | 0/20 | 1/19 |
| NauseaGastrointestinal disorders | 0/20 | 1/20 | 1/19 |
| Abdominal discomfortGastrointestinal disorders | 0/20 | 0/20 | 1/19 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/20 | 0/20 | 1/19 |
| DiarrhoeaGastrointestinal disorders | 0/20 | 1/20 | 0/19 |
| PruritusSkin and subcutaneous tissue disorders | 0/20 | 1/20 | 0/19 |
| Rash maculo-papularSkin and subcutaneous tissue disorders | 0/20 | 1/20 | 0/19 |
| Rash papularSkin and subcutaneous tissue disorders | 0/20 | 1/20 | 0/19 |
Safety Population consisted of all participants who received at least 1 dose of study medication.
| Age, Continuous(Years) | All Treated Participants |
|---|---|
| Mean | 36.4 ± 9.65 |
| Sex: Female, Male(Participants) | All Treated Participants |
|---|---|
| Female | 7 |
| Male | 13 |
| Race/Ethnicity, Customized(Participants) | All Treated Participants |
|---|---|
| Black or African American | 9 |
| White - Arabic/North African Heritage | 2 |
| White - White/Caucasian/European Heritage | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · viivhealthcare.com
Ran from Dec 2020 to primary completion in Mar 2021, 2 months.
Results were first posted in May 2022, 1 year 2 months after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 2 months is below that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: GSK3640254 · Metoprolol · Montelukast · Flurbiprofen · Pravastatin